Agree takeiteasy.
Talk is cheap and all that but by all accounts OXB have a dynamic team in place. |
I think after all of the troubles over the past couple of years and collapsing SP, some brokers may take the view that they want to see 2 or 3 sequential reporting periods ticked off with steady progress before committing to a recommend /buy position.
Each may have their own research protocols to follow which we do not know the details so we can only surmise - but in pure numbers a 50% higher share price target seems to be in the right direction ... |
JPMORGAN RAISES OXFORD BIOMEDICA PRICE TARGET TO 305 (210) PENCE - 'NEUTRAL' |
I would imagine a bigger issue arising from Wuxi’s sanctioning might be a firming up of industry pricing |
Catalent are being bought out by NN to make their slimming drug for American compulsive eaters so probably looking in a different direction now.
Wuxi, well I'd imagine that they would be thrilled with Seb's 2 serious enquiries per week, but what if the US votes to put sanctions on them? |
I wonder how many new CDMO clients are looking to place work with Catalent and Wuxi at the current time. |
Apologies for any confusion. I was simply giving the quote from '21 results which led to the story about building their UK footprint. The year following that MoU becomes the deal as below:-
Oxford Biomedica has signed a 10-year MSDA with Serum Life Sciences Ltd (Serum, a subsidiary of Serum Institute of India), for the manufacture of a variety of vaccine and protein-based therapeutic products. This agreement follows on from the Memorandum of Understanding agreed with Serum in 2021. The MSDA allows for Serum to access the Group’s Oxbox facility to manufacture a variety of vaccines at scales of up to 1,000L.
Serum is also able to secure exclusive access to one of the two new large scale multi 2,000L facilities in the second phase of Oxbox facility expansion for a period of 10 years from facility readiness. Serum will be required to commit to a minimum order value over the relevant period in order to secure exclusive access to the new
large-scale suite. |
So Serum signs a memorandum of understanding a big step forward from reserving manufacturing spaceExpect a deal in a few months more likely weeks |
Looking perky on a pretty drab day |
Stuart's Q&A words from 2021 results day here Phil:-
And that provides a commercial solution, not just for our existing partners on
lenti, but it provides a solution for AAV as well, and then, potentially, other
vaccine work, which we can do. And we've recently signed a memorandum of
understanding with Serum on how a future collaboration will look. We're very
excited by that in terms of us helping them with their strategy of building up
their capacity and capabilities in the UK for vaccine manufacture. |
 The problem with the news is that OXB have said they aren't announcing routine stuff anymore, just as they aren't going to maintain a pipeline page. I'm sure one of the reasons for the latter is simply that it would look bizarre now with something like 30 programme lines all marked confidential / undisclosed.
Roch (in his set piece at the results) rolled out that KPI table again which replaces the pipeline page with simple totals, but without saying how he intends to share it or how often.
Aside from that minor gripe about transparency, we can pretty much say for sure that almost all of our new run of the mill work from now on isn't going to be RNS news.
Back to the assumption here that big news would be the most likely reason none of the insiders bought and what could it be?
You have seen my recurring malaria vaccine guess, but that's 2+ years old now and in that scenario Serum are the contractor to Oxford University and we would be helping Serum meet demand / obligations.
But as they told us at the interims, based on our performance during the pandemic, we seem to have become very favoured by the vaccine lab at Oxford University directly.
So we know (this isn't a guess) that OXB are on with 2 vaccines for Oxford University. These are Middle East Respiratory Syndrome (MERS) and Lassa fever.
MERS is like covid passed by camels and Lassa is a haemorrhaging disease a bit like Ebola.
Why us? Because these vaccines are based upon Oxford’s ChAdOx platform – the same as their COVID-19 vaccine which OXB proved itself really good at making.
Virus and vaccine train spotters amongst us also know that the OU lab got granted a lot of money late last year for the Junín virus vaccine. Junín virus is like Lassa virus but in Argentina and is again based upon the ChAdOx platform, so there's no golden deerstalker as a reward for working out who is prime candidate lined up to make that - and so on.
But I don't think any of that (great though it is) would be big enough to have the insiders all embargoed.
If it's not ever more new early stage work, then surely it has to be something in commercial supply as that is where the big money is. My number 1 guess is still the malaria vaccine work, but a commercial supply deal for someone else would be second. The market size (number of patients) in malaria is enormous, but the vaccine is also very cheap. It's probably equally lucrative for OXB to make a bucketful of something over the same timeframe which is used in rarer treatments which cost 100,000x more. That field is too big to guess from. |
Interesting to note, Serum Life Sciences, the subsidiary of Serum Institute that invested in OXB - are actually UK based, so they may be building a UK footprint rather than just ties to UK businesses for supply, or it could be just a tax efficient vehicle for doing so. |
The Investec analyst has been far from proactive.He's pretty much followed the share price up and down for years.Now he turns a weak buyer following hard on the heels of Stifel's recent note which was nicely timed.The shares seem to have taken a liking to current price levels around 330p after last week's sprint.We might be needing fresh news to trigger further progress. |
I'll gratefully take any good news Edward, but the OXB story has been good for a while now with the post covid troubles all history. The guidance for both what's gone & what's coming has been there for a while and only seems to improve at each update.
Investec rode through all of that with a maintained hold, but now think it's a buy. Something has obviously tipped the balance for them, but as there is nothing new and obvious, presumably the OXB briefing for analysts has been a cracker? |
3.66 - long overdue upgrade as noted by analyst |
If anyone missed it last Monday then the results webcast in now on the OXB website.
Webcast
Transcript |
Page 180 and 273
They have been rating hold since 2021 so something has obviously got them off the pot with a buy. |
nice one - what is the share price mentioned at all - thanks |
Investec raise to buy today |
As I gather the regular posters on this board are in for the long haul (or have already been hauling for a very long time!) we all might benefit from an increased knowledge of the industry. McKinsey have an industry briefing on Cell & Gene Therapy, and while I've not yet read through the articles myself (I will do at the weekend) here is the link. https://www.mckinsey.com/industries/life-sciences/our-insights/mckinsey-insights-on-cell-and-gene-therapy |
End of another chapter in OXB`s history.
AstraZeneca is withdrawing its Covid-19 vaccine worldwide |
That was one oral presentation of the two OXB are presenting at ASGCT24 this week.
They also have 9 posters accepted. 1 about further developing TRiP and 8 others. |
AAV Manufacturing Takes Centre Stage at ASGCT24
Published: May 07, 2024
Oxford Biomedica’s Alex Meola also discussed the use of additives to help isolate the full capsids from not only empty capsids but from a third group that includes a mixture of empty and DNA-containing capsids. “Not all empty capsids are created equal,” he noted, but the company’s proprietary additive combined with the use of anion-exchange chromatography (AEX), which uses AAVs’ positive charge to separate the vectors from impurities during production, was able to increase yield. |
Going to be another million share day in a few minutes.
I preferred this morning at 4% up to this afternoon at 4% down. |
John Evans
@john_evans3
·
2h
We believe BEAM-101 can become the best-in-class editing option for patients with severe SCD, with first data later this year.
John Evans
@john_evans3
·
1h
We are also on track starting up the BEAM-302 trial in the UK for AATD after clearance by the MHRA, and the BEAM-301 US IND is coming soon as well.
Thank you to the team and all our patients and investigators. Lots of progress ahead for base editing in the clinic! |
Register for streaming realtime charts, analysis tools, and prices.
Hot Features
Premium
